#1 Clinical Trials Search in Europe

Ovarian epithelial cancer – Trials in Disease

Go back

Ongoing Clinical Trials for Ovarian Epithelial Cancer

There are currently 18 ongoing clinical trials exploring new treatments for ovarian epithelial cancer across multiple European countries. These studies are testing various therapeutic approaches including targeted therapies, immunotherapies, and chemotherapy combinations for patients at different stages of the disease. The trials include both newly diagnosed and recurrent cases, offering opportunities for patients with platinum-sensitive and platinum-resistant cancers.

Clinical trial locations

Study of JK06 for Patients with Advanced or Metastatic Cancer

This trial is testing JK06, an antibody-drug conjugate, in patients with various advanced cancers including epithelial ovarian cancer. The medication is administered through intravenous infusion every three weeks.

Main inclusion criteria: Patients must be at least 18 years old with confirmed advanced or metastatic cancer that cannot be surgically removed. They should have tried standard treatments or be unable to receive them. For the expansion phase, patients must have specific cancer types with no more than a specified number of previous treatments. Participants need adequate organ function and a performance status of 0 or 1.

Main exclusion criteria: The trial excludes patients who have had recent cancer treatment, those with certain other health conditions, pregnant or breastfeeding women, people with allergies to study medication, individuals unable to follow study procedures, current participants in other clinical trials, and those with certain heart conditions, uncontrolled infections, recent surgeries, or substance abuse history.

Trial focus: The study aims to determine the safety and tolerability of JK06, as well as identify the optimal dose for future studies. It will evaluate the drug’s effects on various advanced cancers through dose escalation and expansion phases, with continuous monitoring for side effects and treatment response.

Investigational drug: JK06 is a 5T4 antibody-drug conjugate that specifically targets cancer cells, combining an antibody with a cytotoxic agent to attack tumors while minimizing damage to healthy tissue.

Study of Mirvetuximab Soravtansine and Bevacizumab for Maintenance in Adults with Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

This trial compares the combination of mirvetuximab soravtansine and bevacizumab with bevacizumab alone as maintenance therapy in patients with platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancer who have responded to platinum-based chemotherapy.

Main inclusion criteria: Patients must be at least 18 years old with platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancer. They must have received between 4 to 8 cycles of platinum-based chemotherapy including bevacizumab, with no disease progression after treatment. Prior BRCA testing is required, and those with positive results must have received PARP inhibitor treatment. Participants need adequate organ function and a performance status of 0 or 1.

Main exclusion criteria: The study excludes patients who do not have platinum-sensitive cancers, those without epithelial ovarian, fallopian tube, or primary peritoneal cancer, non-female patients, and individuals considered part of vulnerable populations.

Trial focus: The study evaluates progression-free survival, comparing how long patients remain cancer-free with combination therapy versus bevacizumab alone. Regular monitoring includes imaging, blood tests, and quality of life assessments.

Investigational drugs: Mirvetuximab soravtansine is an antibody-drug conjugate that targets cancer cells with folate receptor-alpha, delivering anti-cancer agents directly to tumor cells. Bevacizumab blocks protein that helps cancer cells grow new blood vessels, potentially slowing tumor growth.

Study on Adjusting Chemotherapy with Carboplatin and Paclitaxel for Patients with Poor Prognostic Ovarian Cancer

This trial tests a weekly dose-dense regimen of carboplatin and paclitaxel for ovarian cancer patients with poor prognosis due to chemotherapy resistance and incomplete surgical removal. The study compares this approach to standard every-three-week dosing.

Main inclusion criteria: Patients must have high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancer at advanced stage (III or IV). They should have received 3 to 4 cycles of carboplatin-paclitaxel with a poor response (KELIM score less than 1.0) and cancer not suitable for complete surgical removal. Participants need adequate organ function, ECOG performance status of 0-1, and must be at least 18 years old.

Main exclusion criteria: The study excludes patients with poor prognostic cancers not responding to treatment and unable to undergo complete surgical removal, those with poor chemosensitivity, patients with unfavorable KELIM score less than 1.0, male patients, those outside the specified age range, and vulnerable populations.

Trial focus: The study evaluates whether more frequent, smaller doses of chemotherapy improve outcomes compared to standard dosing. It monitors overall response, progression-free survival, and quality of life through regular assessments.

Investigational drugs: Carboplatin interferes with cancer cell DNA to prevent growth and division. Paclitaxel stops cancer cell division by inhibiting their ability to divide. Both are used in combination to assess improved outcomes for challenging cases.

Study on Letrozole Maintenance Therapy for Patients with Epithelial Ovarian Cancer

This double-blind, randomized trial evaluates letrozole as maintenance therapy for epithelial ovarian cancer patients who have completed standard surgery and chemotherapy. Participants receive either letrozole or placebo to assess progression-free survival.

Main inclusion criteria: Female patients aged 18 or older with newly diagnosed epithelial ovarian, fallopian tube, or peritoneal cancer in FIGO Stage II to IV. They must have undergone debulking surgery and received at least 4 cycles of platinum-based chemotherapy. Tumor samples must show at least 1% ER expression. Participants need ECOG performance status of 0-2 and adequate kidney and liver function.

Main exclusion criteria: The study excludes patients without epithelial ovarian cancer, non-female patients, those outside the specified age range, and vulnerable populations.

Trial focus: The study measures progression-free survival to determine if letrozole can extend the time patients live without cancer worsening. Regular monitoring includes health assessments and quality of life evaluations.

Investigational drug: Letrozole is an aromatase inhibitor that reduces estrogen in the body, potentially slowing or stopping growth of certain cancer cells that need estrogen to grow.

Study on Niraparib and Dostarlimab for Patients with Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Not Suitable for Platinum Treatment

This trial compares the combination of niraparib and dostarlimab against physician-selected chemotherapy in patients with recurrent cancer not suitable for platinum-based treatment. The study evaluates overall survival and other outcomes.

Main inclusion criteria: Patients must have recurrent ovarian, fallopian tube, or primary peritoneal cancer unsuitable for platinum treatment, either due to resistance (cancer returning 1-6 months after first platinum treatment) or inability to take platinum. They need ECOG performance status of 0-1, measurable disease, and must be at least 18 years old with adequate organ function and controlled blood pressure if present.

Main exclusion criteria: The study excludes patients without recurrent ovarian, fallopian tube, or primary peritoneal cancer, male patients, and vulnerable populations.

Trial focus: The study assesses whether the niraparib-dostarlimab combination provides better overall survival compared to standard chemotherapy options. Regular monitoring tracks disease progression and treatment side effects.

Investigational drugs: Niraparib blocks enzymes cancer cells need to repair themselves, preventing their growth. Dostarlimab is an immunotherapy that helps the immune system recognize and attack cancer cells by blocking the PD-1 receptor.

Study on Sentinel Node Detection Using Technetium-99m and Indocyanine Green in Patients with Early-Stage Ovarian Cancer

This trial evaluates the effectiveness of two substances, 99mTc albumin nanocolloid and indocyanine green, in detecting sentinel lymph nodes during surgery for early-stage epithelial ovarian cancer. The study aims to improve diagnostic processes and cancer staging.

Main inclusion criteria: Patients must have an adnexal mass with high suspicion of malignancy requiring biopsy during surgery, or previously diagnosed early-stage epithelial ovarian cancer needing complete staging. There should be no signs of cancer spread to retroperitoneal lymph nodes or other body parts on imaging. An informed consent form must be signed, and women of childbearing potential must use effective birth control.

Main exclusion criteria: Only female patients can participate. The study is not open to vulnerable populations requiring special protection or care.

Trial focus: The study assesses diagnostic efficiency of the tracers in detecting sentinel lymph nodes, evaluating detection rates, false negatives, anatomical locations, and concordance between tracers. It also monitors surgical and post-operative complications.

Investigational drugs: 99Tc Albumin Nanocolloid is a radioactive tracer for medical imaging helping locate sentinel lymph nodes. Indocyanine Green is a dye used alongside the radioactive tracer to visualize lymph nodes, helping assess cancer spread.

Study on the Safety and Effectiveness of GTAEXS617 for Patients with Advanced Solid Tumors

This Phase 1/2 trial studies GTAEXS617, a new oral tablet treatment, for patients with advanced solid tumors including ovarian cancer. The study evaluates safety, tolerability, and anti-tumor activity in two modules.

Main inclusion criteria: Patients must be at least 18 years old with confirmed advanced solid tumors that are advanced, recurrent, or have spread after standard treatments. They need ECOG performance status of 0-1, life expectancy over 3 months, ability to swallow oral medication, and adequate blood, liver, and kidney function. Those with biopsable tumor lesions must provide samples.

Main exclusion criteria: The study excludes patients with advanced solid tumors, those outside the specified age range, and vulnerable populations.

Trial focus: Module 1A assesses GTAEXS617 safety alone, Module 1B evaluates safety combined with standard care, Module 2A examines anti-tumor activity alone, and Module 2B assesses activity with standard care. Regular monitoring tracks treatment response and side effects.

Investigational drug: GTAEXS617 is an experimental medication taken as an oral tablet, designed to treat advanced solid tumors. The study evaluates its safety and anti-tumor activity.

Study on the Safety and Effectiveness of IMGN151 for Women with Recurrent Endometrial and Ovarian Cancer

This trial studies IMGN151, an antibody-drug conjugate, for women with recurrent high-grade serous epithelial ovarian, primary peritoneal, or fallopian tube cancer. The study determines the safest effective dose and evaluates treatment effectiveness.

Main inclusion criteria: Female patients at least 18 years old who completed major surgery at least 4 weeks before starting treatment. They need adequate blood, liver, and kidney function, must sign informed consent, and use effective birth control if of childbearing potential with negative pregnancy test. Participants need performance status of 0-1. For Dose-Escalation Phase, confirmed diagnosis of recurrent cancer after trying standard treatments. For Expansion Phase, specific recurrent cancer diagnosis with particular treatment history.

Main exclusion criteria: Non-female patients and those not considered part of vulnerable populations.

Trial focus: The Dose-Escalation Phase identifies the safest effective dose by testing different doses and monitoring side effects. The Expansion Phase gives the chosen dose to more patients for further effectiveness assessment. Throughout, participants receive IMGN151 intravenously with close monitoring.

Investigational drug: IMGN151 is an antibody-drug conjugate that combines an antibody with a drug to target and kill cancer cells, delivering treatment directly to cancer cells while minimizing healthy cell damage.

Study of ETX-19477 for Patients with Advanced Solid Tumors After Standard Treatment

This Phase 1/2 trial tests ETX-19477, a PARG inhibitor taken as an oral capsule, for patients with advanced solid tumors including ovarian cancer that have continued growing despite standard treatments.

Main inclusion criteria: Male or female patients aged 18 or older able to understand and sign informed consent. They must have confirmed advanced solid cancer (incurable, returned, cannot be surgically removed, or spread) excluding primary brain tumors. The cancer must have worsened after recent treatment or patients cannot tolerate treatment. Participants need ECOG performance status of 0-1, life expectancy over 3 months, measurable disease, adequate blood/kidney/liver function, and ability to swallow oral medication.

Main exclusion criteria: Patients without standard treatment for advanced solid tumors, those outside specified age range, unable to understand or comply with procedures, pregnant or breastfeeding, with serious interfering health conditions, currently in another trial, with recent major surgery/injury, history of allergic reactions to similar medications, active infections requiring treatment, and certain uncontrolled heart conditions.

Trial focus: Phase 1 determines the safest tolerable dose and observes side effects. Phase 2 assesses effectiveness in treating cancer. Regular check-ups monitor health and cancer response.

Investigational drug: ETX-19477 is a PARG inhibitor designed to interfere with cancer cell processes, potentially slowing growth or causing cell death by preventing cancer cells from repairing DNA damage.

Study of mirvetuximab soravtansine dosing schedules for patients with platinum-resistant advanced ovarian, peritoneal, or fallopian tube cancer with high folate receptor expression

This trial evaluates different dosing schedules of mirvetuximab soravtansine for platinum-resistant advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancer with high folate receptor expression.

Main inclusion criteria: Female patients aged 18 or older with confirmed high-grade ovarian, peritoneal, or fallopian tube cancer that has progressed after most recent treatment. They must have received 1-3 previous treatments, provide tumor tissue sample or undergo biopsy, have tumors testing positive for FRα protein at required levels, measurable tumors by imaging, good physical function (ECOG 0-1), adequate blood/liver/kidney function, and completed previous treatments within specific timeframes with recovery from side effects.

Main exclusion criteria: Male patients, those under 18, patients with severe liver problems, those not previously receiving platinum-based chemotherapy, patients without high-grade epithelial ovarian/primary peritoneal/fallopian tube cancer resistant to platinum, vulnerable populations, those unable to receive medication every 3 weeks, and patients who cannot be accurately weighed.

Trial focus: The study tests different dosing schedules to determine which works best with least side effects. Patients are randomly assigned schedules, receiving medication through intravenous infusion at 6 mg/kg every 3 weeks in 21-day cycles, with regular monitoring for treatment effectiveness and side effects.

Investigational drug: Mirvetuximab soravtansine targets cancer cells with high folate receptor-alpha levels, delivering anti-cancer drugs directly to cancer cells while reducing effects on healthy cells.

Study of Chemotherapy With Pembrolizumab and Olaparib for Patients With Advanced Epithelial Ovarian Cancer Without BRCA Mutation

This trial compares chemotherapy effectiveness with or without pembrolizumab, followed by olaparib or placebo maintenance treatment, for advanced epithelial ovarian cancer patients without BRCA mutations.

Main inclusion criteria: Female patients with confirmed advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer (high-grade serous, endometrioid, clear cell, carcinosarcoma, mixed mullerian with high-grade serous component, or low-grade serous). They must have just completed or be eligible for primary debulking surgery, or be potential candidates for interval debulking surgery. Participants need good general health (ECOG performance status 0-1), adequate organ function, ability to provide new tumor sample for genetic testing, evidence of BRCA1/2 mutation status, and use of effective birth control if of childbearing potential.

Main exclusion criteria: Patients not newly diagnosed with advanced ovarian/fallopian/primary peritoneal cancer, those without high-grade epithelial cancer, patients not in FIGO stage III-IV, non-female patients, those outside specified age range, and vulnerable populations.

Trial focus: The study evaluates how treatments prevent cancer progression, comparing different approaches including standard chemotherapy with bevacizumab followed by bevacizumab maintenance, versus additional durvalumab or durvalumab-olaparib combinations. Regular monitoring assesses disease progression and treatment response.

Investigational drugs: Pembrolizumab is an immunotherapy helping the immune system attack cancer cells by blocking a protein preventing immune system function. Olaparib targets cancer cells with specific genetic defects, interfering with DNA repair ability to cause cell death as maintenance therapy preventing cancer return.

Summary

The 18 ongoing clinical trials for ovarian epithelial cancer reflect diverse therapeutic approaches across Europe. Several notable patterns emerge from this collection of studies. France, Spain, and Belgium host the most trials, with France leading with 11 trials. Italy and Germany also show significant involvement with 10 and 8 trials respectively.

Targeted therapies feature prominently, with mirvetuximab soravtansine appearing in multiple trials for both platinum-sensitive and platinum-resistant cases. This antibody-drug conjugate specifically targets cancer cells with high folate receptor-alpha expression. PARP inhibitors like olaparib, niraparib, and rucaparib are being studied in various combinations, particularly for maintenance therapy after initial chemotherapy response.

Immunotherapy approaches are well represented, with pembrolizumab, dostarlimab, durvalumab, and nivolumab being tested either alone or in combination with other treatments. Several trials combine immunotherapy with PARP inhibitors or traditional chemotherapy to potentially improve outcomes.

The trials address different disease stages and treatment lines, from newly diagnosed advanced cases to recurrent platinum-resistant cancers. Many studies focus on maintenance therapy following initial treatment response, recognizing the importance of sustaining remission. Patient populations range from those requiring first-line treatment to those who have received multiple prior therapies.

Most trials require participants to have adequate organ function, reasonable performance status, and specific biomarker profiles. Female patients aged 18 and older form the eligible population, with vulnerable populations typically excluded. The studies generally extend through 2025-2029, with regular monitoring for disease progression, treatment response, and quality of life measures.

Ongoing Clinical Trials on Ovarian epithelial cancer

  • Comparing AZD5335 with Mirvetuximab Soravtansine or a drug combination in patients with platinum-resistant ovarian cancer

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Czechia Denmark France Germany Greece +4

  • Study of mirvetuximab soravtansine dosing schedules for patients with platinum-resistant advanced ovarian, peritoneal, or fallopian tube cancer with high folate receptor expression

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Poland Spain

  • Study of JK06 for Patients with Advanced or Metastatic Cancer

    Recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Spain

  • Study on Letrozole Maintenance Therapy for Patients with Epithelial Ovarian Cancer

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Germany

  • Study on Hyperthermic Intraperitoneal Chemotherapy with Cisplatin for Patients with Recurrent Ovarian Cancer

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on Adjusting Chemotherapy with Carboplatin and Paclitaxel for Patients with Poor Prognostic Ovarian Cancer

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Italy The Netherlands

  • Study on the Safety and Effectiveness of GTAEXS617 for Patients with Advanced Solid Tumors

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium

  • Study of ETX-19477 for Patients with Advanced Solid Tumors After Standard Treatment

    Not yet recruiting

    1 1
    Investigated diseases:
    France Italy Spain

  • Study of Mirvetuximab Soravtansine and Bevacizumab for Maintenance in Adults with Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Bulgaria Czechia France Germany Greece +5

  • Study of Rucaparib and Nivolumab for Maintenance Treatment in Patients with Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer After Chemotherapy

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Czechia Denmark Germany Greece Ireland +5

More information about
Ovarian epithelial cancer:

Connected medications: